Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial) - Summary - MDSpire

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)

  • By

  • Xiaojing Chen

  • Lixin Liu

  • Xitong Jin

  • Yanan Cheng

  • Huanwen Wu

  • Yan You

  • Yuligh Liou

  • Pei Liu

  • Jinghe Lang

  • Lei Li

  • June 19, 2026

  • 0 min

Share

Objective:

To explore hypermethylated gene markers in cervical scraped cells that may be associated with endometrial cancer and validate their diagnostic role.

Approach:
    Key Findings:
    • In the validation set, combining methylated CDO1, CELF4, and NEFM achieved a sensitivity of 94.6% (95% confidence interval 85.1-98.9) and a specificity of 92.8% (95% confidence interval 89.3-95.5).
    Interpretation:

    Cervical cytological DNA methylation assays of CDO1, CELF4, and NEFM provide a strategy for detecting endometrial cancer.

    Limitations:
    • The study was conducted at a single center, which may limit generalizability.
    • The sample size for the exploratory cohort was relatively small.
    Conclusion:

    Methylation assays for detecting endometrial cancer in cervical cytological samples show potential as a noninvasive evaluation method.

Original Source(s)

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)

  • by Xiaojing Chen, Lixin Liu, Xitong Jin, Yanan Cheng, Huanwen Wu, Yan You, Yuligh Liou, Pei Liu, Jinghe Lang, Lei Li

  • June 19, 2026

Related Content

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

HuBIE: The human blood immunome encyclopedia of TCRs and BCRs in bloodstream infections and cancer